24/7 Market News Snapshot 04 September, 2025 – Aquestive Therapeutics, Inc. Common Stock (NASDAQ:AQST)

September 4, 2025

DENVER, Colo., 04 September, 2025 (www.247marketnews.com) – (NASDAQ:AQST) are discussed in this article.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is witnessing a notable surge in its stock price, having opened at $3.89 and soared to $4.836, reflecting an impressive increase of over 22%. This upswing follows a previous session close at $3.95, fueled by significant investor interest, as evidenced by a trading volume of 2.10 million shares. The momentum indicates a possible bullish trend for the company, making it a focal point in the biotech sector.

Further underpinning this excitement is the recent announcement concerning AQST’s innovative treatment for severe allergic reactions. The U.S. Food and Drug Administration (FDA) has confirmed that an advisory committee meeting will not be required for its Anaphylm™ (dibutepinephrine) Sublingual Film. This pivotal development places the Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm on January 31, 2026. Positioned as a potential game-changer, Anaphylm aims to be the first FDA-approved, non-invasive epinephrine delivery option for patients at risk of anaphylaxis. Unlike traditional injections that can induce fear and hesitation, this sublingual film offers a practical, needle-free solution that enhances patient compliance.

Dan Barber, President and CEO of Aquestive Therapeutics, conveyed optimism about the FDA’s ruling, emphasizing the film’s potential to transform the treatment landscape for anaphylaxis and improve the quality of life for patients and caregivers. In conjunction with a recent $160 million financing initiative, the company appears well-prepared for a swift market entry following approval.

In addition to Anaphylm, Aquestive is broadening its therapeutic portfolio, demonstrating a commitment to innovation and improving patient care in multiple areas of medicine, solidifying its status as a pioneering force in the pharmaceutical industry.

Related news for (AQST)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.